Cisplatin is one of the most widely used chemotherapeutic agents in the world, and it is particularly important in the treatment of cervical cancer, a disease that disproportionately strikes women in their reproductive years. While oncologists have long documented cisplatin’s toxic effects on the kidneys, ears, and nerves, its consequences for the uterus have received far less attention. This gap matters clinically. For young women with cervical cancer, fertility preservation is a growing priority, and previous reports have described unexplained uterine atrophy in patients who received neoadjuvant chemotherapy before fertility-sparing surgery. A uterus that is structurally or functionally compromised may struggle to support implantation and pregnancy even if the ovaries continue to produce eggs and hormones.

To investigate whether galaxamide could mitigate this damage, the research team, led by corresponding authors Hanlin Shuai, Bihui Guo, and Ping Li, used female mice bearing HeLa cervical cancer tumors. The animals were assigned to receive cisplatin alone or cisplatin in combination with galaxamide, and the researchers then carried out a comprehensive assessment of uterine health. Their measurements spanned multiple levels of biological organization, from gross tissue architecture down to individual signaling proteins. They examined uterine morphology under the microscope, quantified systemic inflammation by measuring circulating cytokines, tracked apoptosis or programmed cell death in the endometrial epithelium, measured the expression of molecules that define endometrial receptivity, characterized the polarization state of macrophages infiltrating the tissue, and probed the activation status of the nuclear factor kappa B, or NF-κB, inflammatory signaling pathway.

The results painted a stark picture of what cisplatin does to the mouse uterus. Animals receiving the chemotherapy drug alone showed thinning of the endometrial epithelium, the single-cell layer lining the uterine cavity, along with disorganization of the endometrial glands, the structures responsible for secreting factors essential for early pregnancy. The endometrial epithelial cells underwent elevated levels of apoptosis, driven by shifts in the expression of genes that regulate the cell death machinery. Beyond cell death, cisplatin disrupted the physical infrastructure of the lining: the integrity of desmosomes and tight junctions, the specialized protein assemblies that glue epithelial cells to one another and maintain the barrier function of the uterus, was compromised. The expression of receptivity markers, the molecular beacons that signal when the endometrium is ready to accept an implanting embryo, dropped significantly. Systemically, the cisplatin-treated mice exhibited elevated serum levels of the inflammatory cytokines interleukin-6, interleukin-18, and tumor necrosis factor-alpha, and their uteri showed increased infiltration of M1 macrophages, the pro-inflammatory subclass of immune cells, accompanied by activation of NF-κB signaling within the tissue.

Galaxamide co-treatment reversed nearly every one of these pathological changes. Mice that received the combination therapy maintained much of their normal uterine architecture, with preserved epithelial thickness and organized glandular structures. Cytokine levels in the blood fell toward baseline, apoptotic gene expression normalized, receptivity markers returned, and the desmosome and tight junction networks retained their integrity. Perhaps most strikingly, galaxamide shifted the immune landscape of the uterus, promoting the polarization of macrophages toward the M2 phenotype, an anti-inflammatory, tissue-repairing state, while simultaneously suppressing the NF-κB pathway that had been driving the inflammatory cascade. The mechanistic story that emerges is one of dual protection: galaxamide both calms inflammation and blocks apoptosis, and it appears to accomplish this largely through inhibition of NF-κB, a master transcription factor that, when activated, enters the nucleus and switches on genes encoding cytokines, survival signals, and additional inflammatory mediators.

The molecular logic of this protection is grounded in established biology. NF-κB has long been implicated in endometrial diseases in both humans and animals, and disturbed endometrial NF-κB expression has been documented in women suffering from recurrent implantation failure. Because NF-κB sits upstream of both inflammatory cytokine production and apoptosis-regulating gene networks, inhibiting it can produce broad downstream benefits, which is consistent with the wide-ranging histological and molecular rescue the researchers observed. Macrophages are also central players in this drama. These immune cells are normal, even essential, residents of the endometrium, where they participate in tissue remodeling during the menstrual cycle and support embryo implantation. But when skewed toward the M1, pro-inflammatory state, they can become a double-edged sword, and prior studies have shown that macrophage-driven inflammation exacerbates cisplatin toxicity in organs as varied as the kidney and the inner ear. By steering macrophages toward the M2 phenotype, galaxamide appears to convert a damaging immune response into a reparative one.

The study builds directly on the group’s earlier work. In 2024, members of the same team reported in BMC Cancer that galaxamide alleviated cisplatin-induced premature ovarian insufficiency in HeLa tumor-bearing mice through the PI3K signaling pathway. Galaxamide has also been shown in separate research to possess intrinsic antitumor activity against cervical cancer cells, driving apoptosis and reducing cancer stem-like properties by inhibiting the Wnt/beta-catenin pathway. Taken together, these findings position galaxamide as an unusually versatile candidate: a compound that may enhance cisplatin’s tumor-killing efficacy, protect the ovaries from chemotherapy-induced dysfunction, and now, according to the new study, protect the uterus as well. The researchers also deposited raw RNA sequencing data from the uterine transcriptomic analysis in the NCBI Gene Expression Omnibus under accession number GSE302127, providing a public resource for other investigators to mine differentially expressed genes and pathway signatures.

For patients and clinicians, the implications are tantalizing but must be interpreted with appropriate caution. The work was performed entirely in mice, and rodent reproductive biology, while sharing many molecular pathways with humans, does not perfectly recapitulate human uterine physiology. Dosing, pharmacokinetics, and long-term safety of galaxamide in humans remain unestablished, and it is not yet known whether the protective effects would extend to chemotherapy regimens beyond cisplatin or to cancer types other than cervical cancer. There is also a theoretical concern that any compound protecting normal tissue from chemotherapy could, in principle, shield tumor cells as well; however, the prior evidence that galaxamide actually increases cisplatin’s antitumor efficacy in this same model argues against that possibility and instead suggests a therapeutic window in which normal tissue is spared while malignant cells remain vulnerable.

The significance of the study also lies in what it reveals about the uterus as a target of chemotherapy toxicity. Research into gonadotoxicity has traditionally centered on the ovaries, where chemotherapy depletes the finite pool of follicles and can trigger premature ovarian insufficiency. Strategies to protect the ovaries, including gonadotropin-releasing hormone agonists and a growing list of cytoprotective natural products such as resveratrol, pycnogenol, and melatonin, have attracted substantial attention. The uterus, by contrast, has been comparatively neglected, even though successful pregnancy depends on far more than oocyte quality: it requires an endometrium with intact epithelial junctions, functional glands, properly timed receptivity marker expression, and a balanced immune environment. The new findings, together with earlier reports that cisplatin decreases the expression of the receptivity factors HOXA13 and integrin alpha-v beta-3 in the uterus, establish that platinum chemotherapy can undermine precisely these receptive features.

The experimental design of the study deserves note for its breadth. By combining histological assessment, ELISA-based cytokine measurement, Western blotting and immunostaining for signaling proteins, gene expression profiling of apoptotic markers, and macrophage phenotyping, the team assembled converging lines of evidence from independent methodologies. The inclusion of a tumor-bearing context is particularly important, because it evaluates the protective compound in the setting where it would actually be used, alongside an active tumor, rather than in healthy animals. The authors report that the work was supported by the National Natural Science Foundation of China and multiple Guangdong provincial research foundations, and the experimental protocols were approved by the Laboratory Animal Committee of Jinan University.

What comes next will likely involve validating these findings in larger animal studies, clarifying exactly how galaxamide inhibits NF-κB signaling at the biochemical level, and determining whether the M2 macrophage shift is a cause or a consequence of the reduced inflammation. If subsequent work confirms the protective effect and establishes safety, galaxamide could join a new generation of oncofertility interventions aimed not merely at preserving the ability to produce eggs, but at safeguarding the entire reproductive tract. For the growing number of young cancer survivors who hope to carry a pregnancy after treatment, that distinction could prove decisive. The study is published in Reproductive Sciences.

In an ambitious effort to tackle this clinical conundrum, investigators led by Dr. Shruti Gupta, MD, MPH, and Dr. David Leaf, MD, MMSc, of Brigham and Women’s Hospital have conducted a comprehensive multicenter cohort study that illuminates a potentially transformative approach to cisplatin nephrotoxicity prevention. Published recently in JAMA Oncology, the research outlines how intravenous magnesium administration on the same day as cisplatin chemotherapy can significantly diminish the risk of AKI, thus offering a pragmatic, cost-effective adjuvant therapy.

The nephrotoxic effects of cisplatin originate primarily from its accumulation in renal proximal tubular cells, where it induces oxidative stress, inflammation, and apoptosis. This cascade leads to impaired kidney function, often manifesting as an acute rise in serum creatinine and subsequent renal impairment. While hydration and dose adjustment remain cornerstones of clinical management, the precise molecular mechanisms of cisplatin-induced kidney injury have spurred exploration into targeted insights. Among these, magnesium’s role in renal physiology and detoxification pathways has garnered increasing attention.

Animal models have long suggested magnesium’s intervention potential, hypothesizing that magnesium supplementation promotes renal excretion of cisplatin and its metabolites, thereby attenuating tubular uptake and cytotoxicity. Despite this biological plausibility, robust evidence from large human populations has been lacking. Drs. Gupta and Leaf’s investigative team therefore designed a rigorous observational study leveraging data from five prominent U.S. cancer centers, encompassing nearly 14,000 patients receiving their first dose of intravenous cisplatin between 2006 and 2022.

This unprecedented cohort study stratified patients based on whether they received intravenous magnesium concurrently with the initial cisplatin administration. Approximately 30% of the cohort received IV magnesium. Employing meticulous statistical adjustments to control for confounding variables—including demographic factors, baseline kidney function, hydration protocols, and comorbidities—the researchers sought to isolate the independent association between magnesium receipt and the incidence of cisplatin-associated AKI.

The results were striking. After adjustment, patients receiving IV magnesium demonstrated a 20% reduction in the odds of developing acute kidney injury compared to those without magnesium supplementation. Importantly, this protective effect was consistent across multiple subgroups stratified by age, cancer type, cisplatin dose, and baseline renal risk. Sensitivity analyses further reinforced the robustness of these findings, underscoring magnesium’s potential as a nephroprotective agent in clinical oncology practice.

Mechanistically, magnesium’s protective role may be multifaceted. Given its critical involvement in cellular enzymatic reactions and membrane stabilization, magnesium infusion may mitigate oxidative damage induced by cisplatin metabolites. Additionally, magnesium appears to modulate renal tubular transporter activity, facilitating cisplatin clearance and reducing localized drug accumulation. This aligns with preclinical evidence that magnesium deficiency exacerbates cisplatin toxicity, while supplementation restores renal resilience.

The clinical implications of this study resonate strongly within oncology and nephrology communities. Magnesium is inexpensive, globally accessible, and carries a well-established safety profile. Integrating IV magnesium infusion into standard supportive care for patients scheduled to undergo cisplatin treatment could represent a straightforward yet impactful strategy to minimize nephrotoxicity. This approach promises to enhance patient quality of life, maintain chemotherapy dose intensity, and ultimately improve cancer treatment outcomes.

However, the authors are cautious to emphasize that despite compelling observational data, definitive confirmation requires randomized controlled trials (RCTs). Recognizing this gap, a pivotal RCT (NCT05730816) is underway at Brigham and Women’s Hospital, designed to prospectively evaluate the efficacy of IV magnesium in preventing cisplatin-associated AKI. Outcomes from this trial are eagerly anticipated and could catalyze paradigm shifts in chemoprotective protocols.

Beyond nephroprotection, magnesium’s role in oncology warrants continued exploration. Emerging evidence suggests systemic magnesium homeostasis influences tumor biology and patient tolerance to other cytotoxic agents. Future research may unravel additional benefits and mechanistic insights, potentially expanding magnesium’s therapeutic relevance beyond renal protection.

This groundbreaking study represents a remarkable example of translational research bridging bench and bedside. By harnessing real-world patient data from multiple institutions and incorporating mechanistic understanding from prior experimental studies, the investigators have delineated a promising pathway to ameliorate a long-standing clinical challenge.

As cisplatin remains a mainstay chemotherapy agent for numerous aggressive malignancies, reducing its adverse impact on patients’ kidneys is paramount. The findings reported by Gupta, Leaf, and colleagues ignite hope for clinicians and patients alike, signaling that a simple intervention such as intravenous magnesium administration could preserve kidney function without compromising anticancer efficacy.

Continued international collaboration and investment in nephro-oncology research will be critical to validate these findings and optimize protocols. Meanwhile, oncologists may consider the emerging evidence when developing individualized treatment plans, particularly for patients at heightened risk for renal complications.

In conclusion, the study titled “Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury: A Multicenter Cohort Study” published in JAMA Oncology marks a significant advance in supportive cancer care. It underscores the power of leveraging existing pharmacological agents to mitigate chemotherapy toxicity, offering a beacon of hope for safer, more tolerable cancer therapies worldwide.

Subject of Research: People
Article Title: Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury
News Publication Date: 24-Apr-2025
Web References: DOI: 10.1001/jamaoncol.2025.0756
References: Gupta S, et al. “Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury: A Multicenter Cohort Study” JAMA Oncology
Image Credits: Not provided
Keywords: Nephropathies, Kidney cancer, Magnesium, Cancer research, Cisplatin, Chemotherapy, Acute kidney injury, Nephrotoxicity